RNA activation of CEBPA improves leukemia treatment
Open Access
- 16 June 2025
- journal article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (3) , 102611
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research
- Canadian Cancer Society (708370)
- Cole Foundation
- Santé (288558)
- Cole Foundation (CIHR PJT-186077)
- Fonds de recherche du Québec
- Canada Research Chairs
- Canada Foundation for Innovation
- Natural Sciences and Engineering Research Council of Canada
This publication has 110 references indexed in Scilit:
- Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemiaActa Biomaterialia, 2024
- Targeting RNA with synthetic oligonucleotides: Clinical success invites new challengesCell Chemical Biology, 2023
- Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatmentBlood Reviews, 2022
- Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivoAnnals of Hematology, 2019
- Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and ImmunityCell, 2019
- Enhancer and Transcription Factor Dynamics during Myeloid Differentiation Reveal an Early Differentiation Block in Cebpa null ProgenitorsCell Reports, 2018
- C/EBPα in normal and malignant myelopoiesisInternational Journal of Hematology, 2015
- Differentiation and Characterization of Myeloid CellsCurrent Protocols in Immunology, 2014
- Role of the Clathrin Terminal Domain in Regulating Coated Pit Dynamics Revealed by Small Molecule InhibitionCell, 2011
- Molecular mechanisms underlying deregulation of C/EBPα in acute myeloid leukemiaInternational Journal of Hematology, 2010